Merdury Biopharmaceutical Corporation Partners with UBI Pharma Inc.(6562.TW) to Pioneer Sildenafil Orally Disintegrating Tablets for the $4.5 Billion Global ED Drug Market 2023 年 11 月 14 日 Read More
UBI Pharma Inc. as received two prestigious awards at the 20th National Brand Yushan Awards (2023) 2023 年 10 月 25 日 Read More
UBI Pharma Inc. has commissioned EirGenix to produce the biosimilar drug UB-851, paving the way for an early international market expansion. 2023 年 10 月 3 日 Read More
UBI Pharma Inc. Passes Ukrainian Inspection, Joining Lumosa Therapeutics to Enter European Market 2023 年 7 月 24 日 Read More
Dialysis Rate in Taiwan is the Highest Worldwide! The Phase III Trial of the EPO Injection Developed by UBI Pharma has been Completed, the Company Plans to Submit an Application for Drug Licensing to the TFDA 2022 年 1 月 20 日 Read More
Successful Unblinding of the Phase III Clinical Trial of Erythropoietin Conducted by UBI Pharma, a Subsidiary of United Biomedical 2021 年 6 月 11 日 Read More
